CAS: 304448-55-3; N'-(3,4-Dihydroxybenzylidene)-3-Hydroxy-2-Naphthohydrazide

上下游产品

CAS号5341-58-2 3-羟基-2-萘酸肼 | CAS号139-85-5 原儿茶醛; 原二茶醛; 茶酚甲...

📜2-羟基-1-萘并肼,3,4-二羟基苯甲醛置于溶剂黄146体系中,用 乙醇 作为反应溶剂,化学反应 4.0H,以40%的收率获得产物n'-(3,4-二羟基亚苄基)-3-羟基-2-萘甲酰肼
参考文献:Kr20220010685A
标题:Kr20220010685A

专利信息

专利号:US-2025011792-A1
优先权日:2021-12-01
标题:Irap inhibitors for use in the treatment of inflammatory diseases
发明人：HERMINE OLIVIER; WEIMERSHAUS MIRJANA; TROVATI MACIEL THIAGO; VAN ENDERT PETER; DUSSIOT MICHAEL; RIGNAULT-BRICARD RACHEL; CARVALHO CAROLINE
权利人:INST NAT SANTE RECH MED; ASSIST PUBLIQUE HOPITAUX PARIS APHP; FOND IMAGINE; UNIV PARIS CITE; CENTRE NAT RECH SCIENT
摘要:Upon activation, mast cells rapidly release preformed inflammatory mediators from large cytoplasmic granules via regulated exocytosis. This acute degranulation is followed by a late activation phase involving synthesis and secretion of cytokines, growth factors and other inflammatory molecules via the constitutive pathway that remains ill-defined. Here the inventors describe a role for an insulin-responsive vesicle-like endosomal compartment, marked by insulin-regulated aminopeptidase (IRAP), in the secretion of TNF-α and IL-6 in mast cells and macrophages. IRAP-deficient mice are protected from TNF-dependent kidney injury and inflammatory arthritis. In the absence of IRAP, TNF fails to be efficiently exported from the Golgi. Chemical targeting of IRAP+ endosomes reduced pro-inflammatory cytokine secretion thereby highlighting this compartment as a promising target for the therapeutic control of inflammation. Thus the present invention relates to the use of IRAP inhibitors for the treatment of inflammatory diseases

专利号:US-2022396794-A1
优先权日:2019-06-04
标题:APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
发明人：HABIB NAGY; ROSSI JOHN; YOON SORAH; SWIDERSK PIOTR MAREK
权利人:APTERNA LTD; HOPE CITY
摘要:Methods of treating or preventing a disease or disorder are disclosed comprising administering to a subject in need thereof an effective amount of a nucleic acid compound comprising, or consisting of, a nucleic acid sequence capable of binding to a transferrin receptor (TfR) and an effective amount of an inhibitor of DNA synthesis. Also disclosed is a nucleic acid compound comprising, or consisting of, a nucleic acid sequence having at least 85% sequence identity to SEQ ID NO: 1, wherein said nucleic acid sequence is at least 30 nucleotides in length and at most 50 nucleotides in length, and wherein the nucleic acid sequence is capable of binding to a transferrin receptor (TfR).